Laminopathies are a group of rare genetic disorders caused by mutations in genes encoding proteins of the nuclear lamina. They are included in the more generic term nuclear envelopathies that was coined in 2000 for diseases associated with defects of the nuclear envelope. Since the first reports of laminopathies in the late 1990s, increased research efforts have started to uncover the vital role of nuclear envelope proteins in cell and tissue integrity in animals.
- 1 Symptoms
- 2 Genetics
- 3 Molecular action
- 4 Treatment and drug development
- 5 List of known laminopathies and other nuclear envelopathies
- 6 References
- 7 External links
- 8 External links
- 9 Sponsors
- 10 Tired of being overweight? W8MD can help! W8MD Weight Loss, Sleep & Aesthetic Services
Laminopathies and other nuclear envelopathies have a large variety of clinical symptoms including skeletal and/or cardiac muscular dystrophy, lipodystrophy and diabetes, dysplasia, dermo- or neuropathy, leukodystrophy, and progeria (premature aging). Most of these symptoms develop after birth, typically during childhood or adolescence. Some laminopathies however may lead to an early death, and mutations of lamin B (LMNB1 gene) may be lethal before or at birth.
More recently, mutations in lamin B (LMNB2 gene) or genetic defects leading to changes in lamin B abundance were identified as cause for laminopathies.
Mutations implicated in other nuclear envelopathies were found in genes coding for lamin-binding proteins such as lamin B receptor (LBR gene), emerin (EMD gene) and LEM domain-containing protein 3 (LEMD3 gene) and prelamin-processing enzymes such as the zinc metalloproteinase STE24 (ZMPSTE24 gene).
The nuclear envelopathy with the highest frequency in human populations is Emery-Dreifuss muscular dystrophy caused by an X-linked mutation in the EMD gene coding for emerin and affecting an estimated 1 in 100,000 people.
Lamins are intermediate filament proteins that form the nuclear lamina scaffold underneath the nuclear envelope in animal cells. They are attached to the nuclear envelope membrane via farnesyl anchors and interaction with inner nuclear membrane proteins such as lamin B receptor and emerin. The nuclear lamina appears to be an adaptation to mobility in animals as sessile organisms such as plants or fungi do not have lamins and the symptoms of many laminopathies include muscle defects. Mutations in these genes might lead to defects in filament assembly and/or attachment to the nuclear envelope and thus jeopardize nuclear envelope stability in physically stressed tissues such as muscle fibers, bone, skin and connective tissue.
Messenger RNA produced from the LMNA gene undergoes alternative splicing and is translated into lamins A and C. Lamin A undergoes farnesylation to attach a membrane anchor to the protein. This version of the protein is also referred to as prelamin A. Farnesylated prelamin A is further processed into mature lamin A by a metalloproteinase removing the last 15 amino acids and its farnesylated cysteine. This allows lamin A to dissociate from the nuclear envelope membrane and fulfill nuclear functions. Mutations causing laminopathies interfere with these processes on different levels.
Nonsense and missense mutations
Missense mutations in the lamin A/C rod and tail domains are the cause for a wide array of genetic disorders, suggesting that lamin A/C protein contains distinct functional domains that are essential for the maintenance and integrity of different cell lineages. Interaction between lamin A and the nuclear envelope protein emerin appears to be crucial in muscle cells, with certain mutations in lamin mimicking mutations in emerin and causing Emery-Dreifuss muscular dystrophy. Different mutations lead to dominant-negative and recessive alleles. Mutations in the lamin rod domain leading to mislocalization of both lamin A and emerin occur in patients with autosomal dominant forms of muscular dystrophy and cardiomyopathy.
Most lamin B mutations appear to be lethal with mutations in lamin B1 causing death at birth in mice. In 2006, lamin B2 missense mutations were identified in patients with acquired partial lipodystrophy.
Mutations causing progeria are defective in splicing LMNA mRNA, therefore producing abnormal lamin A protein, also known as progerin. The mutations activate a cryptic splice site within exon 11 of the gene, thereby causing the deletion of the processing site on prelamin A. This results in an accumulation of progerin that is unable to mature into lamin A, leading to misshapen nuclei. Missplicing also leads to the complete or partial loss of exon 11 and results in a truncated prelamin A protein in the neonatal lethal tight skin contracture syndrome.
Since the metalloproteinase STE24 is required to process prelamin A into mature lamin A, mutations in this gene abolishing protease activity cause defects similar to laminopathies caused by prelamin A with truncated processing sites. Symptoms in patients with ZMPSTE24 mutation range from mandibuloacral dysplasia, progeroid appearance, and generalized lipodystrophy to infant-lethal restrictive dermopathy.
Gene dosage effects
In the case of autosomal dominant leukodystrophy, the disease is associated with a duplication of the lamin B gene LMNB1. The exact dosage of lamin B in cells appears to be crucial for nuclear integrity as increased expression of lamin B causes a degenerative phenotype in fruit flies and leads to abnormal nuclear morphology.
Treatment and drug development
Currently, there is no cure for laminopathies and treatment is largely symptomatic and supportive. Physical therapy and/or corrective orthopedic surgery may be helpful for patients with muscular dystrophies. Cardiac problems that occur with some laminopathies may require a pacemaker. Treatment for neuropathies may include medication for seizures and spasticity.
The recent progress in uncovering the molecular mechanisms of toxic progerin formation in laminopathies leading to premature aging has opened up the potential for the development of targeted treatment. The farnesylation of prelamin A and its pathological form progerin is carried out by the enzyme farnesyl transferase. Farnesyl transferase inhibitors (FTIs) can be used effectively to reduce symptoms in two mouse model systems for progeria and to revert the abnormal nuclear morphology in progeroid cell cultures. Two oral FTIs, lonafarnib and tipifarnib, are already in use as anti-tumor medication in humans and may become avenues of treatment for children suffering from laminopathic progeria. Nitrogen-containing bisphosphate drugs used in the treatment of osteoporosis reduce farnesyldiphosphate production and thus prelamin A farnesylation. Testing of these drugs may prove them to be useful in treating progeria as well. The use of antisense oligonucleotides to inhibit progerin synthesis in affected cells is another avenue of current research into the development of anti-progerin drugs.
List of known laminopathies and other nuclear envelopathies
|Syndrome||OMIM ID||Symptoms||Mutation in||Identified in|
|Atypical Werner syndrome||Progeria with increased severity compared to normal Werner syndrome||Lamin A/C||2003|
|Barraquer-Simons syndrome||Lipodystrophy||Lamin B||2006|
|Buschke-Ollendorff syndrome||Skeletal dysplasia, skin lesions||LEM domain containing protein 3 (lamin-binding protein)||2004|
|Cardiomyopathy, dilated, with quadriceps myopathy||Cardiomyopathy||Lamin A/C||2003|
|Charcot-Marie-Tooth disease, axonal, type 2B1||Neuropathy||Lamin A/C||2002|
|Emery-Dreifuss muscular dystrophy, X-linked (EDMD)||Skeletal and cardiac muscular dystrophy||Emerin (lamin-binding protein)||1996, 2000|
|Emery-Dreifuss muscular dystrophy, autosomal dominant (EDMD2)||Skeletal and cardiac muscular dystrophy||Lamin A/C||1999|
|Emery-Dreifuss muscular dystrophy, autosomal recessive (EDMD3)||Skeletal and cardiac muscular dystrophy||Lamin A/C||2000|
|Familial partial lipodystrophy of the Dunnigan type (FPLD)||Lipoatrophic diabetes||Lamin A/C||2002|
|Greenberg dysplasia||Skeletal dysplasia||Lamin B receptor||2003|
|Hutchinson-Gilford progeria syndrome (HGPS)||Progeria||Lamin A/C||2003|
|Leukodystrophy, demyelinating, adult-onset, autosomal dominant (ADLD)||Progressive demyelinating disorder affecting the central nervous system||Lamin B (tandem gene duplication)||2006|
|Limb-girdle muscular dystrophy type 1B (LGMD1B)||Muscular dystrophy of hips and shoulders, cardiomyopathy||Lamin A/C||2000|
|Lipoatrophy with diabetes, hepatic steatosis, hypertrophic cardiomyopathy, and leukomelanodermic papules (LDHCP)||Lipoatrophic diabetes, fatty liver, hypertrophic cardiomyopathy, skin lesions||Lamin A/C||2003|
|Mandibuloacral dysplasia with type A lipodystrophy (MADA)||Dysplasia and lipodystrophy||Lamin A/C||2002|
|Mandibuloacral dysplasia with type B lipodystrophy (MADB)||Dysplasia and lipodystrophy||Zinc metalloprotease STE24 (prelamin-processing enzyme)||2003|
|Pelger-Huet anomaly (PHA)||Myelodysplasia||Lamin B receptor||2002|
|Pelizaeus-Merzbacher disease, adult-onset, autosomal dominant||Leukodystrophy||Lamin B||2006|
|Tight skin contracture syndrome, lethal||Dermopathy||Lamin A/C or Zinc metalloprotease STE24 (prelamin-processing enzyme)||2004|
- Cite error: Invalid
<ref>tag; name "Padiath" defined multiple times with different content
Our sponsors WikiMD is supported by W8MD weight loss, sleep and medical aesthetic centers. == Also see == Obesity | Diet | Nutrition | Wellness | Encyclopedia of obesity | Weight loss articles | Encyclopedia of weight loss